TG Therapeutics Inc expected to post earnings of 18 cents a share - Earnings Preview

TG Therapeutics

02/05/2025 14:59

TG Therapeutics Inc TGTX.OQ TGTX.O is expected to show a rise in quarterly revenue when it reports  results on May 5 for the period ending March 31 2025

The Morrisville North Carolina-based  company is expected to report a 86.6% increase in revenue to $118.427 million from $63.47 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for TG Therapeutics Inc is for earnings of 18 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for TG Therapeutics Inc is $46.00​, above​ its last closing price of $45.37. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.07
0.08
0.15
Beat
80.7
Sep. 30 2024
0.04
0.03
0.02
Missed
-32.2
Jun. 30 2024
-0.05
-0.05
0.04
Beat
187.5​
Mar. 31 2024
-0.02
-0.04
-0.07
Missed
-96
​​Dec. 31 2023
-0.12
-0.10
-0.10
Met
4.1
Sep. 30 2023
0.05
0.12
0.73
Beat
530.9​
Jun. 30 2023
-0.24
-0.25
-0.34
Missed
-36.7
Mar. 31 2023
-0.38
-0.37
-0.28
Beat
23.7

This summary was machine generated May 2 at 13:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)